The function of α-synuclein

Neuron

Volumn 79, Issue 6, 2013, Pages 1044-1066

  Bendor, JacobT ^a   Logan, ToddP ^a   Edwards, RobertH ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; ISOPROTEIN; SNARE PROTEIN;

CELL MEMBRANE; COMPLEX FORMATION; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; EXOCYTOSIS; GBA1 GENE; GENE INTERACTION; HIPPOCAMPUS; HUMAN; NERVE DEGENERATION; NERVE ENDING; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; SHY DRAGER SYNDROME; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PRIONS;

EID: 84884250340     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.09.004     Document Type: Review

References (317)

1. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Ahlskog J.E. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007, 69:1701-1711.
3. Ahn T.B., Kim S.Y., Kim J.Y., Park S.S., Lee D.S., Min H.J., Kim Y.K., Kim S.E., Kim J.M., Kim H.J., et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008, 70:43-49.
4. Al-Chalabi A., Dürr A., Wood N.W., Parkinson M.H., Camuzat A., Hulot J.S., Morrison K.E., Renton A., Sussmuth S.D., Landwehrmeyer B.G., et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 2009, 4:e7114. NNIPPS Genetic Study Group.
5. Alim M.A., Hossain M.S., Arima K., Takeda K., Izumiyama Y., Nakamura M., Kaji H., Shinoda T., Hisanaga S., Ueda K. Tubulin seeds alpha-synuclein fibril formation. J.Biol. Chem. 2002, 277:2112-2117.
6. Alonso-Canovas A., Katschnig P., Tucci A., Carecchio M., Wood N.W., Edwards M., Martínez Castrillo J.C., Burke D., Heales S., Bhatia K.P. Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: case report and literature review. Mov. Disord. 2010, 25:1506-1509.
7. Annerino D.M., Arshad S., Taylor G.M., Adler C.H., Beach T.G., Greene J.G. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012, 124:665-680.
8. Antonny B. Mechanisms of membrane curvature sensing. Annu. Rev. Biochem. 2011, 80:101-123.
9. Anwar S., Peters O., Millership S., Ninkina N., Doig N., Connor-Robson N., Threlfell S., Kooner G., Deacon R.M., Bannerman D.M., et al. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J.Neurosci. 2011, 31:7264-7274.
10. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H., Yu I., Shah B., Weir D., Thompson C., Szu-Tu C., Trinh J., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 2013, 28:811-813.
11. Assayag K., Yakunin E., Loeb V., Selkoe D.J., Sharon R. Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am. J. Pathol. 2007, 171:2000-2011.
12. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
13. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., Unser M., Aebischer P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:872-887.
14. Bae E.J., Lee H.J., Rockenstein E., Ho D.H., Park E.B., Yang N.Y., Desplats P., Masliah E., Lee S.J. Antibody-aided clearance ofextracellular α-synuclein prevents cell-to-cell aggregate transmission. J.Neurosci. 2012, 32:13454-13469.
15. Barbour R., Kling K., Anderson J.P., Banducci K., Cole T., Diep L., Fox M., Goldstein J.M., Soriano F., Seubert P., Chilcote T.J. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 2008, 5:55-59.
16. Barceló-Coblijn G., Golovko M.Y., Weinhofer I., Berger J., Murphy E.J. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J.Neurochem. 2007, 101:132-141.
17. Bartels T., Choi J.G., Selkoe D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
18. Ben Gedalya T., Loeb V., Israeli E., Altschuler Y., Selkoe D.J., Sharon R. Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 2009, 10:218-234.
19. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J.Biol. Chem. 1999, 274:33855-33858.
20. Bertoncini C.W., Fernandez C.O., Griesinger C., Jovin T.M., Zweckstetter M. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. J.Biol. Chem. 2005, 280:30649-30652.
21. Bisaglia M., Tosatto L., Munari F., Tessari I., de Laureto P.P., Mammi S., Bubacco L. Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 2010, 394:424-428.
22. Bloch A., Probst A., Bissig H., Adams H., Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol. 2006, 32:284-295.
23. Boassa D., Berlanga M.L., Yang M.A., Terada M., Hu J., Bushong E.A., Hwang M., Masliah E., George J.M., Ellisman M.H. Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J.Neurosci. 2013, 33:2605-2615.
24. Bodner C.R., Dobson C.M., Bax A. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J.Mol. Biol. 2009, 390:775-790.
25. Boettcher J.M., Hartman K.L., Ladror D.T., Qi Z., Woods W.S., George J.M., Rienstra C.M. Membrane-induced folding of the cAMP-regulated phosphoprotein endosulfine-alpha. Biochemistry 2008, 47:12357-12364.
26. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
27. Brenz Verca M.S., Bahi A., Boyer F., Wagner G.C., Dreyer J.L. Distribution of alpha- and gamma-synucleins in the adult rat brain and their modification by high-dose cocaine treatment. Eur. J. Neurosci. 2003, 18:1923-1938.
28. Breydo L., Wu J.W., Uversky V.N. A-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 2012, 1822:261-285.
29. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Südhof T.C. Alpha-synuclein promotes SNARE-complex assembly invivo and invitro. Science 2010, 329:1663-1667.
30. Burré J., Vivona S., Diao J., Sharma M., Brunger A.T., Südhof T.C. Properties of native brain α-synuclein. Nature 2013, 498:E4-E6. discussion E6-E7.
31. Busch D.J., Morgan J.R. Synuclein accumulation is associated with cell-specific neuronal death after spinal cord injury. J.Comp. Neurol. 2012, 520:1751-1771.
32. Bussell R., Ramlall T.F., Eliezer D. Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci. 2005, 14:862-872.
33. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., Orrison B., Chen A., Ellis C.E., Paylor R., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J.Neurosci. 2002, 22:8797-8807.
34. Carballo-Carbajal I., Weber-Endress S., Rovelli G., Chan D., Wolozin B., Klein C.L., Patenge N., Gasser T., Kahle P.J. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell. Signal. 2010, 22:821-827.
35. Caumont A.S., Galas M.C., Vitale N., Aunis D., Bader M.F. Regulated exocytosis in chromaffin cells. Translocation of ARF6 stimulates a plasma membrane-associated phospholipase D. J.Biol. Chem. 1998, 273:1373-1379.
36. Chandra S., Fornai F., Kwon H.B., Yazdani U., Atasoy D., Liu X., Hammer R.E., Battaglia G., German D.C., Castillo P.E., Südhof T.C. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. USA 2004, 101:14966-14971.
37. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O.M., Südhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
38. Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8:657-663.
39. Chen L., Jin J., Davis J., Zhou Y., Wang Y., Liu J., Lockhart P.J., Zhang J. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem. Biophys. Res. Commun. 2007, 356:548-553.
40. Chen R.H., Wislet-Gendebien S., Samuel F., Visanji N.P., Zhang G., Marsilio D., Langman T., Fraser P.E., Tandon A. α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J.Biol. Chem. 2013, 288:7438-7449.
41. Chiba-Falek O., Nussbaum R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 2001, 10:3101-3109.
42. Cockcroft S., Way G., O'Luanaigh N., Pardo R., Sarri E., Fensome A. Signalling role for ARF and phospholipase D in mast cell exocytosis stimulated by crosslinking of the high affinity FcepsilonR1 receptor. Mol. Immunol. 2002, 38:1277-1282.
43. Colby D.W., Prusiner S.B. Prions. Cold Spring Harb. Perspect. Biol. 2011, 3:a006833.
44. Cole N.B., Murphy D.D., Grider T., Rueter S., Brasaemle D., Nussbaum R.L. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J.Biol. Chem. 2002, 277:6344-6352.
45. Cole N.B., Dieuliis D., Leo P., Mitchell D.C., Nussbaum R.L. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 2008, 314:2076-2089.
46. Colley W.C., Sung T.C., Roll R., Jenco J., Hammond S.M., Altshuller Y., Bar-Sagi D., Morris A.J., Frohman M.A. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 1997, 7:191-201.
47. Comellas G., Lemkau L.R., Nieuwkoop A.J., Kloepper K.D., Ladror D.T., Ebisu R., Woods W.S., Lipton A.S., George J.M., Rienstra C.M. Structured regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites. J.Mol. Biol. 2011, 411:881-895.
48. Comellas G., Lemkau L.R., Zhou D.H., George J.M., Rienstra C.M. Structural intermediates during α-synuclein fibrillogenesis on phospholipid vesicles. J.Am. Chem. Soc. 2012, 134:5090-5099.
49. Conway K.A., Harper J.D., Lansbury P.T. Accelerated invitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
50. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 2000, 97:571-576.
51. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., Liu K., Xu K., Strathearn K.E., Liu F., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
52. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 1998, 436:309-312.
53. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
54. Dalfó E., Barrachina M., Rosa J.L., Ambrosio S., Ferrer I. Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiol. Dis. 2004, 16:92-97.
55. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 2002, 99:14524-14529.
56. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J.Biol. Chem. 1998, 273:9443-9449.
57. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. USA 2009, 106:13010-13015.
58. Dettmer U., Newman A.J., Luth E.S., Bartels T., Selkoe D. Invivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J.Biol. Chem. 2013, 288:6371-6385.
59. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J.Biol. Chem. 2008, 283:9089-9100.
60. DeWitt D.C., Rhoades E. α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry 2013, 52:2385-2387.
61. Diao J., Burré J., Vivona S., Cipriano D.J., Sharma M., Kyoung M., Südhof T.C., Brunger A.T. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2013, 2:e00592.
62. Dickson D.W., Fujishiro H., Orr C., DelleDonne A., Josephs K.A., Frigerio R., Burnett M., Parisi J.E., Klos K.J., Ahlskog J.E. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 2009, 15(Suppl 3):S1-S5.
63. Dickson D.W., Uchikado H., Fujishiro H., Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S78-S82.
64. Ding Z.T., Wang Y., Jiang Y.P., Hashizume Y., Yoshida M., Mimuro M., Inagaki T., Iwase T. Characteristics of alpha-synucleinopathy in centenarians. Acta Neuropathol. 2006, 111:450-458.
65. Drolet R.E., Behrouz B., Lookingland K.J., Goudreau J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004, 25:761-769.
66. Eliezer D., Kutluay E., Bussell R., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J.Mol. Biol. 2001, 307:1061-1073.
67. Ellis C.E., Murphy E.J., Mitchell D.C., Golovko M.Y., Scaglia F., Barceló-Coblijn G.C., Nussbaum R.L. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell. Biol. 2005, 25:10190-10201.
68. Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S.D., Ntzouni M., Margaritis L.H., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J.Neurosci. 2010, 30:6838-6851.
69. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., Margolis R.L., Troncoso J.C., Lanahan A.A., Worley P.F., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 1999, 22:110-114.
70. Fan Y., Limprasert P., Murray I.V., Smith A.C., Lee V.M., Trojanowski J.Q., Sopher B.L., La Spada A.R. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum. Mol. Genet. 2006, 15:3002-3011.
71. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55:174-179.
72. Farrer M.J., Williams L.N., Algom A.A., Kachergus J., Hulihan M.M., Ross O.A., Rajput A., Papapetropoulos S., Mash D.C., Dickson D.W. Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat. Disord. 2009, 15:414-416.
73. Fauvet B., Mbefo M.K., Fares M.B., Desobry C., Michael S., Ardah M.T., Tsika E., Coune P., Prudent M., Lion N., et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J.Biol. Chem. 2012, 287:15345-15364.
74. Fernández-Chacón R., Wölfel M., Nishimune H., Tabares L., Schmitz F., Castellano-Muñoz M., Rosenmund C., Montesinos M.L., Sanes J.R., Schneggenburger R., Südhof T.C. The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron 2004, 42:237-251.
75. Fleming S.M., Tetreault N.A., Mulligan C.K., Hutson C.B., Masliah E., Chesselet M.F. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 2008, 28:247-256.
76. Fon E.A., Pothos E.N., Sun B.-C., Killeen N., Sulzer D., Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997, 19:1271-1283.
77. Fornai F., Schlüter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA 2005, 102:3413-3418.
78. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J.Neurosci. 2004, 24:6715-6723.
79. Fortin D.L., Nemani V.M., Voglmaier S.M., Anthony M.D., Ryan T.A., Edwards R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J.Neurosci. 2005, 25:10913-10921.
80. Fountaine T.M., Venda L.L., Warrick N., Christian H.C., Brundin P., Channon K.M., Wade-Martins R. The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur. J. Neurosci. 2008, 28:2459-2473.
81. Fujita M., Sugama S., Sekiyama K., Sekigawa A., Tsukui T., Nakai M., Waragai M., Takenouchi T., Takamatsu Y., Wei J., et al. A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun 2010, 1:110.
82. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
83. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. USA 1999, 96:13450-13455.
84. Galvin J.E., Giasson B., Hurtig H.I., Lee V.M., Trojanowski J.Q. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol. 2000, 157:361-368.
85. Galvin J.E., Schuck T.M., Lee V.M., Trojanowski J.Q. Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. Exp. Neurol. 2001, 168:347-355.
86. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995, 15:361-372.
87. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies invitro. J.Biol. Chem. 1999, 274:7619-7622.
88. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
89. Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., Lee V.M. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J.Neurosci. Res. 2000, 59:528-533.
90. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
91. Gillette J.S., Bloomquist J.R. Differential up-regulation of striatal dopamine transporter and alpha-synuclein by the pyrethroid insecticide permethrin. Toxicol. Appl. Pharmacol. 2003, 192:287-293.
92. Gispert S., Del Turco D., Garrett L., Chen A., Bernard D.J., Hamm-Clement J., Korf H.W., Deller T., Braak H., Auburger G., Nussbaum R.L. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 2003, 24:419-429.
93. Gitler A.D., Bevis B.J., Shorter J., Strathearn K.E., Hamamichi S., Su L.J., Caldwell K.A., Caldwell G.A., Rochet J.C., McCaffery J.M., et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105:145-150.
94. Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1101-1118.
95. Goedert M., Spillantini M.G., Del Tredici K., Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013, 9:13-24.
96. Goers J., Manning-Bog A.B., McCormack A.L., Millett I.S., Doniach S., Di Monte D.A., Uversky V.N., Fink A.L. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 2003, 42:8465-8471.
97. Gohil K., Schock B.C., Chakraborty A.A., Terasawa Y., Raber J., Farese R.V., Packer L., Cross C.E., Traber M.G. Gene expression profile of oxidant stress and neurodegeneration in transgenic mice deficient in alpha-tocopherol transfer protein. Free Radic. Biol. Med. 2003, 35:1343-1354.
98. Golbe L.I., Di Iorio G., Sanges G., Lazzarini A.M., La Sala S., Bonavita V., Duvoisin R.C. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann. Neurol. 1996, 40:767-775.
99. Golovko M.Y., Faergeman N.J., Cole N.B., Castagnet P.I., Nussbaum R.L., Murphy E.J. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 2005, 44:8251-8259.
100. Golovko M.Y., Rosenberger T.A., Faergeman N.J., Feddersen S., Cole N.B., Pribill I., Berger J., Nussbaum R.L., Murphy E.J. Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry 2006, 45:6956-6966.
101. Golovko M.Y., Rosenberger T.A., Feddersen S., Faergeman N.J., Murphy E.J. Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. J.Neurochem. 2007, 101:201-211.
102. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., Sondel J., Kotilinek L., Day J., Schwarzschild M.A., et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 2003, 24:245-258.
103. Gonçalves S., Outeiro T.F. Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol. Neurobiol. 2013, 47:1081-1092.
104. Greten-Harrison B., Polydoro M., Morimoto-Tomita M., Diao L., Williams A.M., Nie E.H., Makani S., Tian N., Castillo P.E., Buchman V.L., Chandra S.S. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl. Acad. Sci. USA 2010, 107:19573-19578.
105. Guo J.L., Covell D.J., Daniels J.P., Iba M., Stieber A., Zhang B., Riddle D.M., Kwong L.K., Xu Y., Trojanowski J.Q., Lee V.M. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 2013, 154:103-117.
106. Guschina I., Millership S., O'Donnell V., Ninkina N., Harwood J., Buchman V. Lipid classes and fatty acid patterns are altered in the brain of γ-synuclein null mutant mice. Lipids 2011, 46:121-130.
107. Hamilton R.L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10:378-384.
108. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001, 32:213-223.
109. Herrera F.E., Chesi A., Paleologou K.E., Schmid A., Munoz A., Vendruscolo M., Gustincich S., Lashuel H.A., Carloni P. Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE 2008, 3:e3394.
110. Hoyer W., Cherny D., Subramaniam V., Jovin T.M. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation invitro. Biochemistry 2004, 43:16233-16242.
111. Hua H., Xu L., Wang J., Jing J., Luo T., Jiang Y. Up-regulation of gamma-synuclein contributes to cancer cell survival under endoplasmic reticulum stress. J.Pathol. 2009, 217:507-515.
112. Hughes W.E., Elgundi Z., Huang P., Frohman M.A., Biden T.J. Phospholipase D1 regulates secretagogue-stimulated insulin release in pancreatic beta-cells. J.Biol. Chem. 2004, 279:27534-27541.
113. Humeau Y., Vitale N., Chasserot-Golaz S., Dupont J.L., Du G., Frohman M.A., Bader M.F., Poulain B. A role for phospholipase D1 in neurotransmitter release. Proc. Natl. Acad. Sci. USA 2001, 98:15300-15305.
114. Ibáñez P., Bonnet A.M., Débarges B., Lohmann E., Tison F., Pollak P., Agid Y., Dürr A., Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
115. Inaba S., Li C., Shi Y.E., Song D.Q., Jiang J.D., Liu J. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res. Treat. 2005, 94:25-35.
116. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
117. Iwanaga K., Wakabayashi K., Yoshimoto M., Tomita I., Satoh H., Takashima H., Satoh A., Seto M., Tsujihata M., Takahashi H. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999, 52:1269-1271.
118. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345:27-32.
119. Jao C.C., Der-Sarkissian A., Chen J., Langen R. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. USA 2004, 101:8331-8336.
120. Jao C.C., Hegde B.G., Chen J., Haworth I.S., Langen R. Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc. Natl. Acad. Sci. USA 2008, 105:19666-19671.
121. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 1985, 82:2173-2177.
122. Jellinger K.A. Synuclein deposition and non-motor symptoms in Parkinson disease. J.Neurol. Sci. 2011, 310:107-111.
123. Jellinger K.A., Lantos P.L. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 2010, 119:657-667.
124. Jenco J.M., Rawlingson A., Daniels B., Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 1998, 37:4901-4909.
125. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J.Biol. Chem. 1998, 273:26292-26294.
126. Jensen M.B., Bhatia V.K., Jao C.C., Rasmussen J.E., Pedersen S.L., Jensen K.J., Langen R., Stamou D. Membrane curvature sensing by amphipathic helices: a single liposome study using α-synuclein and annexin B12. J.Biol. Chem. 2011, 286:42603-42614.
127. Ji H., Liu Y.E., Jia T., Wang M., Liu J., Xiao G., Joseph B.K., Rosen C., Shi Y.E. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 1997, 57:759-764.
128. Jo E., McLaurin J., Yip C.M., St George-Hyslop P., Fraser P.E. alpha-Synuclein membrane interactions and lipid specificity. J.Biol. Chem. 2000, 275:34328-34334.
129. Jo E., Fuller N., Rand R.P., St George-Hyslop P., Fraser P.E. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J.Mol. Biol. 2002, 315:799-807.
130. Junn E., Lee K.W., Jeong B.S., Chan T.W., Im J.Y., Mouradian M.M. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. USA 2009, 106:13052-13057.
131. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J.Neurosci. 2000, 20:6365-6373.
132. Kamp F., Exner N., Lutz A.K., Wender N., Hegermann J., Brunner B., Nuscher B., Bartels T., Giese A., Beyer K., et al. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 2010, 29:3571-3589.
133. Kholodilov N.G., Neystat M., Oo T.F., Lo S.E., Larsen K.E., Sulzer D., Burke R.E. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J.Neurochem. 1999, 73:2586-2599.
134. Kim M., Jung W., Lee I.H., Bhak G., Paik S.R., Hahn J.S. Impairment of microtubule system increases alpha-synuclein aggregation and toxicity. Biochem. Biophys. Res. Commun. 2008, 365:628-635.
135. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A., Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 2006, 21:541-548.
136. Kontopoulos E., Parvin J.D., Feany M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 2006, 15:3012-3023.
137. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
138. Krueger M.J., Singer T.P., Casida J.E., Ramsay R.R. Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem. Biophys. Res. Commun. 1990, 169:123-128.
139. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the geneencoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
140. Kubo S.I., Nemani V.M., Chalkley R.J., Anthony M.D., Hattori N., Mizuno Y., Edwards R.H., Fortin D.L. A combinatorial code for the interaction of alpha-synuclein with membranes. J.Biol. Chem. 2005, 280:31664-31672.
141. Kuo Y.M., Li Z., Jiao Y., Gaborit N., Pani A.K., Orrison B.M., Bruneau B.G., Giasson B.I., Smeyne R.J., Gershon M.D., Nussbaum R.L. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19:1633-1650.
142. Larsen K.E., Schmitz Y., Troyer M.D., Mosharov E., Dietrich P., Quazi A.Z., Savalle M., Nemani V., Chaudhry F.A., Edwards R.H., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J.Neurosci. 2006, 26:11915-11922.
143. Lashuel H.A., Overk C.R., Oueslati A., Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 2013, 14:38-48.
144. Lee H.J., Choi C., Lee S.J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J.Biol. Chem. 2002, 277:671-678.
145. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99:8968-8973.
146. Lee H.J., Khoshaghideh F., Patel S., Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J.Neurosci. 2004, 24:1888-1896.
147. Lee H.J., Patel S., Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J.Neurosci. 2005, 25:6016-6024.
148. Lee H.J., Khoshaghideh F., Lee S., Lee S.J. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci. 2006, 24:3153-3162.
149. Lee H.J., Suk J.E., Patrick C., Bae E.J., Cho J.H., Rho S., Hwang D., Masliah E., Lee S.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J.Biol. Chem. 2010, 285:9262-9272.
150. Lee S.J., Desplats P., Sigurdson C., Tsigelny I., Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010, 6:702-706.
151. Lee H.J., Kang S.J., Lee K., Im H. Human α-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1. Biochem. Biophys. Res. Commun. 2011, 412:526-531.
152. Leftin A., Job C., Beyer K., Brown M.F. Solid-state C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein alpha-synuclein. J.Mol. Biol. 2013, 425:2973-2987.
153. Lesage S., Anheim M., Letournel F., Bousset L., Honoré A., Rozas N., Pieri L., Madiona K., Dürr A., Melki R., et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, for the French Parkinson's Disease Genetics (PDG) Study Group, Published online March 22, 2013. 10.1002/ana.23894.
154. Leverenz J.B., Hamilton R., Tsuang D.W., Schantz A., Vavrek D., Larson E.B., Kukull W.A., Lopez O., Galasko D., Masliah E., et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008, 18:220-224.
155. Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001, 40:11604-11613.
156. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., Lee M.K. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J.Neurosci. 2004, 24:7400-7409.
157. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jäkälä P., Hartmann T., Price D.L., Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. USA 2005, 102:2162-2167.
158. Li W.W., Yang R., Guo J.C., Ren H.M., Zha X.L., Cheng J.S., Cai D.F. Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 2007, 18:1543-1546.
159. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Björklund A., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
160. Liani E., Eyal A., Avraham E., Shemer R., Szargel R., Berg D., Bornemann A., Riess O., Ross C.A., Rott R., Engelender S. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl. Acad. Sci. USA 2004, 101:5500-5505.
161. Liu Y., Peter D., Roghani A., Schuldiner S., Privé G.G., Eisenberg D., Brecha N., Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
162. Liu Y., Roghani A., Edwards R.H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 1992, 89:9074-9078.
163. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., Yang H., Uéda K., Chan P., Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454:187-192.
164. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2002, 99:10813-10818.
165. Luk K.C., Song C., O'Brien P., Stieber A., Branch J.R., Brunden K.R., Trojanowski J.Q., Lee V.M. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 2009, 106:20051-20056.
166. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
167. Luk K.C., Kehm V.M., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J.Exp. Med. 2012, 209:975-986.
168. Mak S.K., McCormack A.L., Manning-Bog A.B., Cuervo A.M., Di Monte D.A. Lysosomal degradation of alpha-synuclein invivo. J.Biol. Chem. 2010, 285:13621-13629.
169. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J.Biol. Chem. 2002, 277:1641-1644.
170. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J.Neurosci. 2003, 23:3095-3099.
171. Manning-Boǧ A.B., Schüle B., Langston J.W. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009, 30:1127-1132.
172. Markesbery W.R., Jicha G.A., Liu H., Schmitt F.A. Lewy body pathology in normal elderly subjects. J.Neuropathol. Exp. Neurol. 2009, 68:816-822.
173. Maroteaux L., Scheller R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 1991, 11:335-343.
174. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J.Neurosci. 1988, 8:2804-2815.
175. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J.Neurosci. 2006, 26:41-50.
176. Marui W., Iseki E., Nakai T., Miura S., Kato M., Uéda K., Kosaka K. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J.Neurol. Sci. 2002, 195:153-159.
177. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 2001, 8:535-539.
178. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
179. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872. Consortium on DLB.
180. McLean P.J., Ribich S., Hyman B.T. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. J.Neural Transm. Suppl. 2000, 2000:53-63.
181. McLean P.J., Kawamata H., Hyman B.T. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001, 104:901-912.
182. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 2011, 12:517-533.
183. McNulty B.C., Young G.B., Pielak G.J. Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder. J.Mol. Biol. 2006, 355:893-897.
184. Mendez I., Viñuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., Tierney T., Holness R., Dagher A., Trojanowski J.Q., Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 2008, 14:507-509.
185. Middleton E.R., Rhoades E. Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys. J. 2010, 99:2279-2288.
186. Miller D.W., Johnson J.M., Solano S.M., Hollingsworth Z.R., Standaert D.G., Young A.B. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J.Neural Transm. 2005, 112:1613-1624.
187. Millership S., Ninkina N., Guschina I.A., Norton J., Brambilla R., Oort P.J., Adams S.H., Dennis R.J., Voshol P.J., Rochford J.J., Buchman V.L. Increased lipolysis and altered lipid homeostasis protect γ-synuclein-null mutant mice from diet-induced obesity. Proc. Natl. Acad. Sci. USA 2012, 109:20943-20948.
188. Mim C., Unger V.M. Membrane curvature and its generation by BAR proteins. Trends Biochem. Sci. 2012, 37:526-533.
189. Mizuno N., Varkey J., Kegulian N.C., Hegde B.G., Cheng N., Langen R., Steven A.C. Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. J.Biol. Chem. 2012, 287:29301-29311.
190. Mori F., Tanji K., Yoshimoto M., Takahashi H., Wakabayashi K. Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 2002, 941:118-126.
191. Mosharov E.V., Gong L.W., Khanna B., Sulzer D., Lindau M. Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J.Neurosci. 2003, 23:5835-5845.
192. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., Krantz D.E., Kobayashi K., Edwards R.H., Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
193. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N.Engl. J. Med. 2013, 369:233-244. Multiple-System Atrophy Research Collaboration.
194. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J.Neurosci. 2000, 20:3214-3220.
195. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Role of alpha-synuclein carboxy-terminus on fibril formation invitro. Biochemistry 2003, 42:8530-8540.
196. Nakamura K., Nemani V.M., Wallender E.K., Kaehlcke K., Ott M., Edwards R.H. Optical reporters for the conformation of α-synuclein reveal a specific interaction with mitochondria. J.Neurosci. 2008, 28:12305-12317.
197. Nakamura K., Nemani V.M., Azarbal F., Skibinski G., Levy J.M., Egami K., Munishkina L., Zhang J., Gardner B., Wakabayashi J., et al. Directmembrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J.Biol. Chem. 2011, 286:20710-20726.
198. Narendra D., Walker J.E., Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Cold Spring Harb. Perspect. Biol. 2012, 4:1-19.
199. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J.Biol. Chem. 1999, 274:9843-9846.
200. Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., Chaudhry F.A., Nicoll R.A., Edwards R.H. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
201. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996, 89:691-694.
202. Ninkina N., Peters O., Millership S., Salem H., van der Putten H., Buchman V.L. Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum. Mol. Genet. 2009, 18:1779-1794.
203. Ninkina N., Peters O.M., Connor-Robson N., Lytkina O., Sharfeddin E., Buchman V.L. Contrasting effects of α-synuclein and γ-synuclein on the phenotype of cysteine string protein α (CSPα) null mutant mice suggest distinct function of these proteins in neuronal synapses. J.Biol. Chem. 2012, 287:44471-44477.
204. Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H., Wakabayashi K. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 2004, 107:292-298.
205. Nishie M., Mori F., Yoshimoto M., Takahashi H., Wakabayashi K. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol. Appl. Neurobiol. 2004, 30:546-554.
206. Nishioka K., Wider C., Vilariño-Güell C., Soto-Ortolaza A.I., Lincoln S.J., Kachergus J.M., Jasinska-Myga B., Ross O.A., Rajput A., Robinson C.A., et al. Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch. Neurol. 2010, 67:970-975.
207. Noorian A.R., Rha J., Annerino D.M., Bernhard D., Taylor G.M., Greene J.G. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol. Dis. 2012, 48:9-19.
208. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J.Biol. Chem. 2005, 280:21212-21219.
209. Ohtake H., Limprasert P., Fan Y., Onodera O., Kakita A., Takahashi H., Bonner L.T., Tsuang D.W., Murray I.V., Lee V.M., et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63:805-811.
210. Olanow C.W., Prusiner S.B. Is Parkinson's disease a prion disorder?. Proc. Natl. Acad. Sci. USA 2009, 106:12571-12572.
211. Orimo S., Uchihara T., Nakamura A., Mori F., Kakita A., Wakabayashi K., Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008, 131:642-650.
212. Ouberai M.M., Wang J., Swann M.J., Galvagnion C., Guilliams T., Dobson C.M., Welland M.E. α-Synuclein Senses Lipid Packing Defects and Induces Lateral Expansion of Lipids Leading to Membrane Remodeling. J.Biol. Chem. 2013, 288:20883-20895.
213. Oueslati A., Fournier M., Lashuel H.A. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 2010, 183:115-145.
214. Outeiro T.F., Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003, 302:1772-1775.
215. Ozawa T., Healy D.G., Abou-Sleiman P.M., Ahmadi K.R., Quinn N., Lees A.J., Shaw K., Wullner U., Berciano J., Moller J.C., et al. The alpha-synuclein gene in multiple system atrophy. J.Neurol. Neurosurg. Psychiatry 2006, 77:464-467. European MSA study group.
216. Paik S.R., Shin H.J., Lee J.H., Chang C.S., Kim J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 1999, 340:821-828.
217. Paillusson S., Clairembault T., Biraud M., Neunlist M., Derkinderen P. Activity-dependent secretion of alpha-synuclein by enteric neurons. J.Neurochem. 2013, 125:512-517.
218. Paleologou K.E., Oueslati A., Shakked G., Rospigliosi C.C., Kim H.Y., Lamberto G.R., Fernandez C.O., Schmid A., Chegini F., Gai W.P., et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J.Neurosci. 2010, 30:3184-3198.
219. Pan Z.Z., Bruening W., Giasson B.I., Lee V.M., Godwin A.K. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J.Biol. Chem. 2002, 277:35050-35060.
220. Papp M.I., Lantos P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994, 117:235-243.
221. Parton R.G., del Pozo M.A. Caveolae as plasma membrane sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 2013, 14:98-112.
222. Payton J.E., Perrin R.J., Woods W.S., George J.M. Structural determinants of PLD2 inhibition by alpha-synuclein. J.Mol. Biol. 2004, 337:1001-1009.
223. Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity invivo. J.Neurosci. 2007, 27:3338-3346.
224. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J.Biol. Chem. 2001, 276:41958-41962.
225. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
226. Postuma R.B., Aarsland D., Barone P., Burn D.J., Hawkes C.H., Oertel W., Ziemssen T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov. Disord. 2012, 27:617-626.
227. Pranke I.M., Morello V., Bigay J., Gibson K., Verbavatz J.M., Antonny B., Jackson C.L. α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J.Cell Biol. 2011, 194:89-103.
228. Proukakis C., Dudzik C.G., Brier T., MacKay D.S., Cooper J.M., Millhauser G.L., Houlden H., Schapira A.H. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013, 80:1062-1064.
229. Prusiner S.B. Shattuck lecture-neurodegenerative diseases and prions. N.Engl. J. Med. 2001, 344:1516-1526.
230. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J.Neurochem. 2001, 76:637-640.
231. Quilty M.C., Gai W.P., Pountney D.L., West A.K., Vickers J.C. Localization of alpha-, beta-, and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. Exp. Neurol. 2003, 182:195-207.
232. Rappley I., Gitler A.D., Selvy P.E., LaVoie M.J., Levy B.D., Brown H.A., Lindquist S., Selkoe D.J. Evidence that alpha-synuclein does not inhibit phospholipase D. Biochemistry 2009, 48:1077-1083.
233. Rappley I., Myers D.S., Milne S.B., Ivanova P.T., Lavoie M.J., Brown H.A., Selkoe D.J. Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J.Neurochem. 2009, 111:15-25.
234. Rekas A., Knott R.B., Sokolova A., Barnham K.J., Perez K.A., Masters C.L., Drew S.C., Cappai R., Curtain C.C., Pham C.L. The structure of dopamine induced alpha-synuclein oligomers. Eur. Biophys. J. 2010, 39:1407-1419.
235. Rendón W.O., Martínez-Alonso E., Tomás M., Martínez-Martínez N., Martínez-Menárguez J.A. Golgi fragmentation is Rab and SNARE dependent in cellular models of Parkinson's disease. Histochem. Cell Biol. 2013, 139:671-684.
236. Ribeiro C.S., Carneiro K., Ross C.A., Menezes J.R., Engelender S. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J.Biol. Chem. 2002, 277:23927-23933.
237. Rideout H.J., Stefanis L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell. Neurosci. 2002, 21:223-238.
238. Rideout H.J., Dietrich P., Savalle M., Dauer W.T., Stefanis L. Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. J.Neurochem. 2003, 84:803-813.
239. Rideout H.J., Lang-Rollin I., Stefanis L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int. J. Biochem. Cell Biol. 2004, 36:2551-2562.
240. Robertson D.C., Schmidt O., Ninkina N., Jones P.A., Sharkey J., Buchman V.L. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J.Neurochem. 2004, 89:1126-1136.
241. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., Lansbury P.T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J.Mol. Neurosci. 2004, 23:23-34.
242. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 2001, 914:48-56.
243. Ross O.A., Braithwaite A.T., Skipper L.M., Kachergus J., Hulihan M.M., Middleton F.A., Nishioka K., Fuchs J., Gasser T., Maraganore D.M., et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 2008, 63:743-750.
244. Rott R., Szargel R., Haskin J., Bandopadhyay R., Lees A.J., Shani V., Engelender S. α-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. USA 2011, 108:18666-18671.
245. Sato K., Kaji R., Matsumoto S., Nagahiro S., Goto S. Compartmental loss of striatal medium spiny neurons in multiple system atrophy of parkinsonian type. Mov. Disord. 2007, 22:2365-2370.
246. Sato H., Kato T., Arawaka S. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of invivo models. Rev. Neurosci. 2013, 24:115-123.
247. Sawaya M.R., Sambashivan S., Nelson R., Ivanova M.I., Sievers S.A., Apostol M.I., Thompson M.J., Balbirnie M., Wiltzius J.J., McFarlane H.T., et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 2007, 447:453-457.
248. Schlüter O.M., Fornai F., Alessandrí M.G., Takamori S., Geppert M., Jahn R., Südhof T.C. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003, 118:985-1002.
249. Scholz S.W., Houlden H., Schulte C., Sharma M., Li A., Berg D., Melchers A., Paudel R., Gibbs J.R., Simon-Sanchez J., et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 2009, 65:610-614.
250. Scott D.A., Tabarean I., Tang Y., Cartier A., Masliah E., Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J.Neurosci. 2010, 30:8083-8095.
251. Segarane B., Li A., Paudel R., Scholz S., Neumann J., Lees A., Revesz T., Hardy J., Mathias C.J., Wood N.W., et al. Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 2009, 72:1185-1186.
252. Seidel K., Schöls L., Nuber S., Petrasch-Parwez E., Gierga K., Wszolek Z., Dickson D., Gai W.P., Bornemann A., Riess O., et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann. Neurol. 2010, 67:684-689.
253. Senior S.L., Ninkina N., Deacon R., Bannerman D., Buchman V.L., Cragg S.J., Wade-Martins R. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 2008, 27:947-957.
254. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA 2000, 97:4897-4902.
255. Shannon K.M., Keshavarzian A., Dodiya H.B., Jakate S., Kordower J.H. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 2012, 27:716-719.
256. Sharma M., Burré J., Südhof T.C. CSPα promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. Nat. Cell Biol. 2011, 13:30-39.
257. Sharma M., Burré J., Bronk P., Zhang Y., Xu W., Südhof T.C. CSPα knockout causes neurodegeneration by impairing SNAP-25 function. EMBO J. 2012, 31:829-841.
258. Sharon R., Goldberg M.S., Bar-Josef I., Betensky R.A., Shen J., Selkoe D.J. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA 2001, 98:9110-9115.
259. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
260. Sharon R., Bar-Joseph I., Mirick G.E., Serhan C.N., Selkoe D.J. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J.Biol. Chem. 2003, 278:49874-49881.
261. Shults C.W., Rockenstein E., Crews L., Adame A., Mante M., Larrea G., Hashimoto M., Song D., Iwatsubo T., Tsuboi K., Masliah E. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J.Neurosci. 2005, 25:10689-10699.
262. Shvadchak V.V., Yushchenko D.A., Pievo R., Jovin T.M. The mode of α-synuclein binding to membranes depends on lipid composition and lipid to protein ratio. FEBS Lett. 2011, 585:3513-3519.
263. Sidransky E., Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012, 11:986-998.
264. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N.Engl. J. Med. 2009, 361:1651-1661.
265. Simón-Sánchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
266. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
267. Smith W.W., Jiang H., Pei Z., Tanaka Y., Morita H., Sawa A., Dawson V.L., Dawson T.M., Ross C.A. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum. Mol. Genet. 2005, 14:3801-3811.
268. Smith W.W., Margolis R.L., Li X., Troncoso J.C., Lee M.K., Dawson V.L., Dawson T.M., Iwatsubo T., Ross C.A. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J.Neurosci. 2005, 25:5544-5552.
269. Soma H., Yabe I., Takei A., Fujiki N., Yanagihara T., Sasaki H. Heredity in multiple system atrophy. J.Neurol. Sci. 2006, 240:107-110.
270. Soper J.H., Roy S., Stieber A., Lee E., Wilson R.B., Trojanowski J.Q., Burd C.G., Lee V.M. Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell 2008, 19:1093-1103.
271. Specht C.G., Tigaret C.M., Rast G.F., Thalhammer A., Rudhard Y., Schoepfer R. Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol. Cell. Neurosci. 2005, 28:326-334.
272. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
273. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 1998, 251:205-208.
274. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95:6469-6473.
275. Stefanis L., Kholodilov N., Rideout H.J., Burke R.E., Greene L.A. Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J.Neurochem. 2001, 76:1165-1176.
276. Stichel C.C., Zhu X.R., Bader V., Linnartz B., Schmidt S., Lübbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum. Mol. Genet. 2007, 16:2377-2393.
277. Taschenberger G., Toloe J., Tereshchenko J., Akerboom J., Wales P., Benz R., Becker S., Outeiro T.F., Looger L.L., Bähr M., et al. β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann. Neurol. 2013, Published online March 28, 2013. 10.1002/ana.23905.
278. Thomas B., Mandir A.S., West N., Liu Y., Andrabi S.A., Stirling W., Dawson V.L., Dawson T.M., Lee M.K. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PLoS ONE 2011, 6:e16706.
279. Tofaris G.K., Layfield R., Spillantini M.G. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 2001, 509:22-26.
280. Tofaris G.K., Garcia Reitböck P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M., Spillantini M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J.Neurosci. 2006, 26:3942-3950.
281. Tofaris G.K., Kim H.T., Hourez R., Jung J.W., Kim K.P., Goldberg A.L. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. USA 2011, 108:17004-17009.
282. Trojanowski J.Q., Goedert M., Iwatsubo T., Lee V.M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 1998, 5:832-837.
283. Tsigelny I.F., Bar-On P., Sharikov Y., Crews L., Hashimoto M., Miller M.A., Keller S.H., Platoshyn O., Yuan J.X., Masliah E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 2007, 274:1862-1877.
284. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44:415-422.
285. Uchikado H., Lin W.L., DeLucia M.W., Dickson D.W. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J.Neuropathol. Exp. Neurol. 2006, 65:685-697.
286. Uéda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:11282-11286.
287. Ulmer T.S., Bax A., Cole N.B., Nussbaum R.L. Structure and dynamics of micelle-bound human alpha-synuclein. J.Biol. Chem. 2005, 280:9595-9603.
288. Ulusoy A., Febbraro F., Jensen P.H., Kirik D., Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci. 2010, 32:409-422.
289. Unni V.K., Weissman T.A., Rockenstein E., Masliah E., McLean P.J., Hyman B.T. Invivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS ONE 2010, 5:e10589.
290. Uversky V.N., Li J., Souillac P., Millett I.S., Doniach S., Jakes R., Goedert M., Fink A.L. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J.Biol. Chem. 2002, 277:11970-11978.
291. van Ham T.J., Thijssen K.L., Breitling R., Hofstra R.M., Plasterk R.H., Nollen E.A. C.elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 2008, 4:e1000027.
292. Varkey J., Isas J.M., Mizuno N., Jensen M.B., Bhatia V.K., Jao C.C., Petrlova J., Voss J.C., Stamou D.G., Steven A.C., Langen R. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J.Biol. Chem. 2010, 285:32486-32493.
293. Varkey J., Mizuno N., Hegde B.G., Cheng N., Steven A.C., Langen R. α-Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. J.Biol. Chem. 2013, 288:17620-17630.
294. Vitale N., Caumont A.S., Chasserot-Golaz S., Du G., Wu S., Sciorra V.A., Morris A.J., Frohman M.A., Bader M.F. Phospholipase D1: a key factor for the exocytotic machinery in neuroendocrine cells. EMBO J. 2001, 20:2424-2434.
295. Vogiatzi T., Xilouri M., Vekrellis K., Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J.Biol. Chem. 2008, 283:23542-23556.
296. Volles M.J., Lansbury P.T. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J.Mol. Biol. 2007, 366:1510-1522.
297. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001, 40:7812-7819.
298. Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., Meaney D.F., Trojanowski J.Q., Lee V.M. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
299. Wakabayashi K., Fukushima T., Koide R., Horikawa Y., Hasegawa M., Watanabe Y., Noda T., Eguchi I., Morita T., Yoshimoto M., et al. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and lewy body pathology. Acta Neuropathol. 2000, 99:331-336.
300. Wakamatsu M., Ishii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.
301. Wang L., Fleming S.M., Chesselet M.F., Taché Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19:873-876.
302. Wang W., Perovic I., Chittuluru J., Kaganovich A., Nguyen L.T., Liao J., Auclair J.R., Johnson D., Landeru A., Simorellis A.K., et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA 2011, 108:17797-17802.
303. Watts J.C., Giles K., Stöhr J., Oehler A., Bhardwaj S., Grillo S.K., Patel S., DeArmond S.J., Prusiner S.B. Spontaneous generation of rapidly transmissible prions in transgenic mice expressing wild-type bank vole prion protein. Proc. Natl. Acad. Sci. USA 2012, 109:3498-3503.
304. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
305. Westphal C.H., Chandra S.S. Monomeric synucleins generate membrane curvature. J.Biol. Chem. 2013, 288:1829-1840.
306. Wietek J., Haralampiev I., Amoussouvi A., Herrmann A., Stöckl M. Membrane bound α-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain. FEBS Lett. 2013, 587:2572-2577.
307. Willingham S., Outeiro T.F., DeVit M.J., Lindquist S.L., Muchowski P.J. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 2003, 302:1769-1772.
308. Withers G.S., George J.M., Banker G.A., Clayton D.F. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 1997, 99:87-94.
309. Woods W.S., Boettcher J.M., Zhou D.H., Kloepper K.D., Hartman K.L., Ladror D.T., Qi Z., Rienstra C.M., George J.M. Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J.Biol. Chem. 2007, 282:34555-34567.
310. Yamaguchi K., Cochran E.J., Murrell J.R., Polymeropoulos M.H., Shannon K.M., Crowther R.A., Goedert M., Ghetti B. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol. 2005, 110:298-305.
311. Yavich L., Tanila H., Vepsäläinen S., Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J.Neurosci. 2004, 24:11165-11170.
312. Yavich L., Jäkälä P., Tanila H. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J.Neurochem. 2006, 99:724-732.
313. Yazawa I., Giasson B.I., Sasaki R., Zhang B., Joyce S., Uryu K., Trojanowski J.Q., Lee V.M. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45:847-859.
314. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
315. Zeniou-Meyer M., Zabari N., Ashery U., Chasserot-Golaz S., Haeberlé A.M., Demais V., Bailly Y., Gottfried I., Nakanishi H., Neiman A.M., et al. Phospholipase D1 production of phosphatidic acid at the plasma membrane promotes exocytosis of large dense-core granules at a late stage. J.Biol. Chem. 2007, 282:21746-21757.
316. Zhu M., Fink A.L. Lipid binding inhibits alpha-synuclein fibril formation. J.Biol. Chem. 2003, 278:16873-16877.
317. Zigoneanu I.G., Yang Y.J., Krois A.S., Haque E., Pielak G.J. Interaction of α-synuclein with vesicles that mimic mitochondrial membranes. Biochim. Biophys. Acta 2012, 1818:512-519.